A conventional trial’s eligibility criteria are built to be checked once, against population-level thresholds: an age range, a lab value cutoff, a diagnosis confirmed by a standard test. A committee overseeing that kind of trial is reviewing aggregate data and making judgments about the trial as a whole. Therapies built around an individual patient’s genetic profile, biomarker status, or cellular material change that. Eligibility, dosing, and endpoint interpretation increasingly depend on characteristics specific to one patient, which means more of the committee’s real work happens one patient at a time rather than at the level of the trial overall.
Eligibility Becomes a Judgment Call, Not a Checkbox
When an inclusion criterion is a genetic variant or a biomarker threshold rather than a simple demographic cutoff, confirming that a specific patient qualifies is rarely a mechanical yes or no. It often depends on interpreting an assay result, a borderline value, or a case where two tests disagree, which is exactly the kind of judgment a committee, not a form, exists to make. A trial that treats this as a checkbox to be completed by whoever screens the patient is quietly moving a real clinical decision out of the process built to govern it.
Recognizing this changes what “oversight” means for this kind of trial. It is not only periodic review of aggregate safety and efficacy data. It includes a defined path for escalating an ambiguous per-patient eligibility question to the people with the authority and expertise to resolve it, and a record of how each of those questions was actually resolved.
Endpoints Get Harder to Read in Aggregate
The same shift affects how a committee reads outcome data. A therapy with a genetically or biomarker-defined patient population may show a meaningful effect in a subgroup that is diluted or obscured when the full enrolled population is analyzed together. A committee that only ever sees pooled results can miss a signal that a more granular, biomarker-stratified view would show clearly, or can be misled by an aggregate result that looks unremarkable while masking real variation underneath it.
This does not argue for abandoning aggregate review. It argues for a committee having access to data organized at the level the biology actually operates, rather than only at the level a traditional report happens to summarize it, so that the review reflects how the therapy actually behaves rather than how convenient the data is to compile.
Explaining a Per-Patient Decision Is Its Own Task
When eligibility or a dosing adjustment turns on a specific genetic or biomarker result, the person affected, and often that person’s family or referring physician, may reasonably want to understand why the decision came out the way it did. A committee that reaches a defensible internal decision but cannot articulate the reasoning behind it in terms someone outside the committee can follow has only done half the job. This is a different skill from making the decision itself, and a process that only captures the outcome, qualifies or does not qualify, proceeds at this dose or does not, without also capturing the reasoning in an accessible form, leaves the committee unable to answer the follow-up question when it inevitably comes.
This is not a case for simplifying the science to make it easier to explain. It is a case for treating the explanation as a required output of the decision process, alongside the decision itself, rather than something reconstructed under pressure after the fact when a patient, a site, or an auditor asks for it.
More Decisions, Not Just More Complex Ones
The practical consequence for oversight is less about any single decision being harder and more about there being more decisions that require a documented, defensible rationale. A trial making frequent per-patient eligibility and dosing calls generates a correspondingly larger set of individual decisions that a committee needs to be able to account for later, each one tied to the specific patient data that supported it. A process built for a small number of population-level decisions per review cycle does not scale cleanly to a trial generating many patient-level ones between cycles.
The Committee’s Expertise Has to Match the Decisions It Is Making
A committee assembled to oversee a conventional trial is typically staffed for population-level statistical and safety review. A committee overseeing a therapy where eligibility and dosing turn on individual genetic or biomarker results needs, at minimum, ready access to the specific expertise required to interpret those results correctly, whether that means a geneticist, a specialist in the relevant biomarker assay, or someone who can speak to how a borderline result should be read. Without that expertise available at the point the judgment call is actually made, the committee is left approving or rejecting a recommendation it cannot independently evaluate, which is oversight in name only.
Building a Process That Scales to the Decision Volume
The answer is not a heavier version of a conventional oversight process. It is a process designed around the actual shape of the decisions a personalized-therapy trial produces: a defined path for escalating ambiguous per-patient questions, data organized so a committee can review it at the resolution the therapy requires, and a record connecting each decision to the specific data behind it, available on demand rather than reconstructed after the fact. For sponsors and academic medical centers moving into more genetically and biomarker-defined therapeutic areas, that kind of governed, traceable process is what keeps oversight matched to how the therapy actually works, rather than to how a more conventional trial used to be reviewed.